What it's for (Indications)
- Nepafenac ophthalmic suspension is indicated for the treatment of pain and inflammation associated with cataract surgery.
- Its primary role is to alleviate ocular discomfort and reduce inflammatory responses in the anterior segment of the eye following surgical intervention.
- This includes the prevention and treatment of post-operative pain, photophobia, and the reduction of inflammatory mediators such that visual recovery is optimized.
- The anti-inflammatory effect is crucial in preventing complications like cystoid macular edema (CME), which can significantly impact visual acuity after cataract extraction.
- Its use commences pre-operatively and continues post-operatively for a specified duration to ensure comprehensive control of surgical sequelae.
Dosage Information
| Type | Guideline |
|---|---|
| Standard | The recommended dosage for nepafenac ophthalmic suspension typically involves instilling one drop into the affected eye(s) three times daily starting 1 day prior to cataract surgery, continuing on the day of surgery, and for two weeks post-operatively. For some formulations, a once-daily dosing regimen may be prescribed. Patients should be instructed to shake the bottle well before each use to ensure uniform suspension of the active ingredient. Care must be taken to avoid contamination of the dropper tip by not touching the eye, eyelids, or any other surface with the tip. If more than one topical ophthalmic medication is being used, they should be administered at least 5 minutes apart to prevent washout and ensure proper absorption of each drug. The precise duration of treatment should be determined by the treating ophthalmologist based on the patient's specific condition and surgical outcome. |
Safety & Warnings
Common Side Effects
- Commonly reported side effects associated with nepafenac ophthalmic suspension include, but are not limited to, decreased visual acuity, foreign body sensation, ocular discomfort or irritation, increased intraocular pressure (IOP), blurred vision, eye pruritus, and sticky sensation.
- Less common but more serious adverse reactions can involve the cornea, such as keratitis (including punctate keratitis), corneal thinning, corneal erosion, corneal ulceration, and in severe cases, corneal perforation.
- These corneal events are particularly noted in patients with compromised corneas or those undergoing complicated surgeries.
- Other reported adverse events include headache, dry eye, and photophobia.
- Patients should be advised to report any persistent or worsening symptoms to their ophthalmologist promptly to assess for potential serious complications and adjust treatment if necessary.
Serious Warnings
- Black Box Warning: **Serious Warnings: Potential for Corneal Adverse Events** While nepafenac ophthalmic suspension does not carry an official FDA "Black Box Warning," clinicians and patients must be aware of significant risks, particularly related to the cornea. The use of topical nonsteroidal anti-inflammatory drugs (NSAIDs), including nepafenac, may lead to serious and potentially sight-threatening corneal adverse events. These include, but are not limited to, keratitis, corneal thinning, corneal erosion, corneal ulceration, and in severe instances, corneal perforation. These risks are significantly elevated in patients with compromised corneas, such as those with pre-existing ocular surface diseases (e.g., severe dry eye syndrome), corneal epithelial defects, diabetes mellitus, rheumatoid arthritis, or those who have undergone complicated or recurrent ocular surgeries within a short timeframe. Prolonged use beyond the recommended duration may also exacerbate these risks. Patients should be closely monitored for signs of corneal damage, and treatment should be discontinued immediately if any signs of corneal compromise are observed. NSAIDs can also slow or delay wound healing, potentially impacting post-surgical recovery.
- Nepafenac ophthalmic suspension should be used with caution, particularly in patients with pre-existing ocular conditions or risk factors for corneal complications.
- Prolonged use of topical NSAIDs, including nepafenac, can increase the risk of corneal adverse events such as keratitis, corneal thinning, erosion, ulceration, and perforation, which may be sight-threatening.
- Patients with complicated ocular surgeries, corneal denervation, corneal epithelial defects, diabetes mellitus, ocular surface diseases (e.
- g.
- , dry eye syndrome), rheumatoid arthritis, or repeat ocular surgeries within a short period may be at increased risk.
- Topical NSAIDs may also slow or delay healing.
- Patients wearing contact lenses should be advised to remove them prior to instillation of nepafenac and wait at least 15 minutes before reinserting them, as the preservative benzalkonium chloride can be absorbed by soft contact lenses.
- NSAIDs are not anti-infective agents, and their use may mask signs of ocular infection.
- There is a potential for cross-sensitivity to acetylsalicylic acid, phenylacetic acid derivatives, and other NSAIDs.
How it Works (Mechanism of Action)
Nepafenac is a nonsteroidal anti-inflammatory drug (NSAID) administered as a prodrug. Upon topical ophthalmic instillation, it rapidly penetrates the cornea. Within the ocular tissues, particularly in the iris-ciliary body and retina/choroid, nepafenac undergoes enzymatic hydrolysis by intraocular hydrolases to its active metabolite, amfenac. Amfenac is a potent inhibitor of cyclooxygenase-1 (COX-1) and cyclooxygenase-2 (COX-2), the enzymes responsible for the synthesis of prostaglandins. Prostaglandins are lipid compounds that act as crucial mediators of inflammation, pain, and blood-aqueous barrier breakdown in various ocular tissues. By inhibiting prostaglandin synthesis, amfenac effectively reduces the inflammatory response, alleviating pain and swelling associated with ocular surgical procedures, specifically cataract surgery. This mechanism ensures targeted anti-inflammatory activity directly within the eye while minimizing systemic exposure.
Commercial Brands (Alternatives)
No other brands found for this formula.